Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Collagen Corp. and ABC's 20/20

This article was originally published in The Gray Sheet

Executive Summary

At a March 30 session of the HIMA annual meeting, John Stossel, reporter for the ABC television program 20/20, said he will consider doing a story that provides data from studies indicating that use of Collagen's Zyderm/Zyplast injectable collagen products is not associated with autoimmune disease. A Stossel report on the Feb. 22, 1991 broadcast of 20/20 highlighted claims from individuals who believe that Collagen's products have caused autoimmune disorders ("The Gray Sheet" March 4, 1991, p. 6). Noting that plaintiffs attorneys told him that use of Collagen's products "would lead to all kinds of autoimmune disease," Stossel told the HIMA gathering that "given that the product is in a lot of places, you would think [autoimmune disease] would start showing up all over, and so far it hasn't. And if that continues down the road, and collagen is widely accepted, then I think...I should do a followup story" on how "the emphasis of our story was wrong".

You may also be interested in...

Incyte Ready To Go For Approval Of Topical Ruxolitinib In Atopic Dermatitis

With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.

Axcella Addresses Metabolic Disease Quickly With GRAS Candidates

Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.

Performance Issues With CDC’s COVID-19 Assay Reagent Slows Rollout Of Test Kits To US States

A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts